Thyroid disorders — including hypothyroidism, hyperthyroidism, Hashimoto's thyroiditis, Graves' disease, thyroid nodules, and thyroid cancer — collectively affect an estimated 20 million Americans, making thyroid disease one of the most prevalent endocrine conditions in the country. Yet surveys consistently find that nearly 60% of those with thyroid disease are unaware of their condition — a staggering undiagnosis rate for a condition with a simple, inexpensive blood test (TSH) that can detect it years before symptoms become disabling. The clinical landscape of thyroid disease management is being reshaped by ongoing debates about optimal TSH targets, combination T3/T4 therapy, the thyroid-autoimmunity connection, and the significance of subclinical dysfunction.
TSH: Reference Range vs. Optimal Range
TSH (thyroid-stimulating hormone) is the gold standard screening and monitoring test for thyroid function, with a reference range of approximately 0.4–4.0 mIU/L in most US laboratories. This range is derived from population distributions that include individuals with subclinical thyroid disease — leading some endocrinologists to argue that the true "normal" range should be tightened to 0.5–2.5 mIU/L for most adults. Observational studies associate TSH levels above 2.5 mIU/L with higher rates of atherosclerosis, dyslipidemia, depression, and cognitive decline in certain populations; the ATA and other societies do not yet endorse TSH targets below 4.0 for general screening, but many functional medicine and thyroid specialists target 1.0–2.0 mIU/L in symptomatic treated patients.
Hashimoto's Thyroiditis: Autoimmune Architecture
Hashimoto's thyroiditis — the most common cause of hypothyroidism in iodine-sufficient countries, and the most common autoimmune disease overall — is driven by lymphocytic infiltration of the thyroid gland, ultimately destroying thyroid follicular cells. The diagnosis is established by elevated anti-TPO (thyroid peroxidase) antibodies in the context of hypothyroid biochemistry or classic ultrasound pattern (heterogeneous, hypoechoic gland with increased vascularity). Autoimmune thyroid disease has a strong genetic component (2–3× higher concordance in identical twins) and clusters with other autoimmune conditions including Type 1 diabetes, rheumatoid arthritis, and celiac disease. Selenium supplementation (200 mcg/day) has been shown in multiple meta-analyses to reduce anti-TPO antibody titers and improve quality of life in Hashimoto's patients — one of the few nutritional interventions with meaningful evidence in this condition.
T4 Monotherapy vs. Combination T3/T4
Standard treatment for hypothyroidism is levothyroxine (T4) monotherapy — which is converted to active T3 (triiodothyronine) in peripheral tissues. However, 10–15% of patients on T4 monotherapy continue to report fatigue, cognitive impairment, and quality-of-life deficits despite normalized TSH, driving interest in combination T3/T4 therapy. The DIO2 gene (deiodinase type 2, responsible for T4-to-T3 conversion) polymorphism Thr92Ala — present in approximately 12% of the population in homozygous form — impairs T3 generation from T4 and may identify patients who preferentially benefit from combination therapy. Multiple small trials of levothyroxine + liothyronine (T3) show improved patient-reported quality of life without achieving broader guideline endorsement; the ATA 2014 guidelines acknowledge combination therapy may be appropriate in selected symptomatic patients failing T4 monotherapy. Healthcare facilities can find relevant patient care supplies in our catalog.
